Department of Management, FSA ULaval - Business School, 2325, rue de la Terrasse, Pavillon Palasis-Prince, office 0533, Université Laval, Québec, Québec, G1V 0A6, Canada.
FSA ULaval - Business School, 2325, rue de la Terrasse, Pavillon Palasis-Prince, Université Laval, Québec, Québec, G1V 0A6, Canada.
Patient Educ Couns. 2019 Nov;102(11):2001-2009. doi: 10.1016/j.pec.2019.06.008. Epub 2019 Jun 15.
To support the introduction of pharmacogenomic tests in current practice, this study identifies the factors associated with a better understanding of the information related to genetic, genomic and/or pharmacogenomic tests by patients and health care professionals.
Following a scoping review methodology, a search for literature was conducted with keywords related to health literacy and knowledge translation in the context of pharmacogenomic tests. Since only 6 articles were identified, the context of genetic or genomic testing were added to the inclusion criteria, leading to 24 articles.
Fourteen of the studies analyzed focused on genetic predictive, diagnostic or carrier tests, or concerned genetics in general, while ten addressed or included the use of pharmacogenomic tests. Demographic, individual, experiential and contextual factors were associated with a better understanding of the information related to genetic, genomic and/or pharmacogenomic tests among the targeted populations.
Our review shows that there is currently little empirical research available to identify the factors to consider in order to develop educational tools and resources specific to pharmacogenomics.
Expanding our review to include genetic and genomic testing factors can serve as a starting point for the evidence to be validated in future empirical research.
为了支持将药物基因组学检测引入当前实践，本研究旨在确定与患者和医疗保健专业人员更好地理解与遗传、基因组和/或药物基因组学检测相关信息相关的因素。
采用范围综述方法，针对与药物基因组学检测背景下的健康素养和知识转化相关的关键词进行文献检索。由于仅确定了 6 篇文章，因此将遗传或基因组检测的背景添加到纳入标准中，最终纳入了 24 篇文章。
分析的 14 项研究侧重于遗传预测、诊断或携带者检测，或涉及一般遗传学，而 10 项研究涉及或包括药物基因组学检测的使用。在目标人群中，人口统计学、个体、经验和背景因素与更好地理解与遗传、基因组和/或药物基因组学检测相关的信息有关。
我们的综述表明，目前几乎没有可用的经验研究来确定在开发特定于药物基因组学的教育工具和资源时需要考虑的因素。
将我们的综述扩展到包括遗传和基因组检测因素，可以作为未来经验研究中验证证据的起点。
